Neuroprostheses uses electrodes to interface with the central or peripheral nervous system to restore lost motor or sensory capabilities. These devices can receive neural signals from the external environment & brain, and convert the signals to restore functions such as loss of hearing and vision. They have applications in cognitive disorders, ophthalmic disorders, motor disorders, and auditory disorders.
Expected Revenue Growth:
The neuroprosthetics market is projected to reach USD 10.48 billion by 2022 from USD 5.84 billion in 2017, at a CAGR of 12.4%. The major factors driving the growth of this market are the increasing number of patients suffering from neurological disorders and nerve injury, growing incidence of hearing loss, increasing cases of amputations due to the rising number of accidents & injuries, and increasing prevalence of diabetes.
Driver: Increasing prevalence of diabetes:
People suffering from diabetes may develop several foot problems, which cause damage to blood vessels and nerves. Diabetes can also damage the blood vessels in the retina, which can cause vision impairments or blindness. As a result, the increasing incidence of diabetes is expected to support the growth of the retinal/bionic eye implants market. The top five countries with the highest diabetic population in 2013 (age group of 20–79 years) were China, India, the US, Brazil, and the Russian Federation.
Download PDF Brochure@
Restraints: Availability of alternative treatment options
Novel therapies, such as stem cell therapy, are showcasing a significant potential for the effective treatment of various neurological disorders. Stem cell therapy is an emerging branch of medicine that has the potential to restore organ and tissue function in patients suffering from serious injuries or chronic diseases. These therapies offer advantages such as higher recovery rates and faster recovery periods for patients. Moreover, stem cells also have significant potential in the treatment of motor neuron disease, Parkinson’s disease, and Alzheimer’s disease
Furthermore, medicinal, physical, occupational, and speech therapies are available for the treatment of several neurological disorders. For instance, currently, the preference for drug therapies is higher among Parkinson’s patients due to the lower cost and convenience of the treatment. The availability of these alternative treatment options is one of the significant factors limiting the demand for and adoption of neuroprosthetic devices and implants among the target patient population.
Recent Developments in the Global Neuroprosthetics Market:
# In 2017, Medtronic (US) received FDA approval for the Intellis Platform Spinal Cord Stimulator (SCS).
# In 2017, Abbott Laboratories (US) acquired St. Jude Medical (US) to strengthen its position in the neuroprosthetics market.
# In 2017, Cochlear (Australia) signed an agreement with Otoconsult NV (Belgium) to develop artificial intelligence technology, which helps the company strengthen its cochlear implant portfolio.
# In 2017 Retina Implant AG (Germany) underwent a merger with Okuvision (Germany) to strengthen its position in the neuroprosthetics market.
# In 2016, Boston Scientific (US) acquired Cosman Medical (US) to add the spinal cord stimulator and deep brain stimulation systems to its product portfolio.
Opportunities: Expanded target applications and new indications
Neuroprosthetic procedures involve minimally invasive techniques as opposed to alternate surgical procedures for treating tremors primarily associated with Parkinson’s, which are invasive treatments. For instance, in a pallidotomy, the surgeon destroys a tiny part of the globus pallidus by creating a scar to reduce brain activity. Doctors do not prefer this procedure and encourage the use of deep brain stimulation; instead, as it does not destroy brain tissue and has fewer risks as compared to pallidotomy.
The use of DBS in newer applications/indications, such as Alzheimer’s, epilepsy, and depression, is currently in clinical trials. Similarly, the treatment of heart failure, sleep apnea, obesity, and tinnitus through VNS (Vagus Nerve Stimulation); fecal incontinence by SNS (Sacral Nerve Stimulation); and tinnitus, migraine, and stroke by TMS (Transcranial Magnetic Stimulation) are also under clinical trials. TMS is currently used to treat depression, SNS for urine incontinence, and VNS for epilepsy.
Request Sample Pages@
North America is expected to command the largest share of the market during the forecast period.
Based on region, the neuroprosthetics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2017, North America is expected to command the largest share of the neuroprosthetics market. The large share of this market can primarily be attributed to the high incidence of vision and hearing loss, rising prevalence of neurological disorders, and the strong presence of industry players in this region.